HRP20040686B1 - Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza - Google Patents

Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza

Info

Publication number
HRP20040686B1
HRP20040686B1 HRP20040686AA HRP20040686A HRP20040686B1 HR P20040686 B1 HRP20040686 B1 HR P20040686B1 HR P20040686A A HRP20040686A A HR P20040686AA HR P20040686 A HRP20040686 A HR P20040686A HR P20040686 B1 HRP20040686 B1 HR P20040686B1
Authority
HR
Croatia
Prior art keywords
lactamases
inhibitors
beta
active
heterocyclic compounds
Prior art date
Application number
HRP20040686AA
Other languages
English (en)
Croatian (hr)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Alan Rowlands
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040686(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel filed Critical Novexel
Publication of HRP20040686A2 publication Critical patent/HRP20040686A2/hr
Publication of HRP20040686B1 publication Critical patent/HRP20040686B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20040686AA 2002-01-28 2003-01-27 Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza HRP20040686B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (2)

Publication Number Publication Date
HRP20040686A2 HRP20040686A2 (en) 2004-12-31
HRP20040686B1 true HRP20040686B1 (hr) 2013-02-28

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040686AA HRP20040686B1 (hr) 2002-01-28 2003-01-27 Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza

Country Status (44)

Country Link
US (4) US7612087B2 (OSRAM)
EP (2) EP2279737B1 (OSRAM)
JP (1) JP4472346B2 (OSRAM)
KR (1) KR100979079B1 (OSRAM)
CN (3) CN101406471A (OSRAM)
AR (2) AR038234A1 (OSRAM)
AT (1) ATE484281T1 (OSRAM)
AU (1) AU2003214335B2 (OSRAM)
BE (1) BE2016C069I2 (OSRAM)
BR (1) BRPI0307267B8 (OSRAM)
CA (1) CA2474043C (OSRAM)
CL (1) CL2011000009A1 (OSRAM)
CO (1) CO5601014A2 (OSRAM)
CR (2) CR7387A (OSRAM)
CY (3) CY1111061T1 (OSRAM)
DE (1) DE60334527D1 (OSRAM)
DK (2) DK1480644T3 (OSRAM)
EA (1) EA007220B1 (OSRAM)
EC (1) ECSP045193A (OSRAM)
ES (2) ES2356813T3 (OSRAM)
FR (2) FR2835186B1 (OSRAM)
HR (1) HRP20040686B1 (OSRAM)
HU (1) HUS1600055I1 (OSRAM)
IL (1) IL163167A (OSRAM)
JO (1) JO2646B1 (OSRAM)
LT (1) LTC1480644I2 (OSRAM)
MA (1) MA26351A1 (OSRAM)
MX (1) MXPA04006621A (OSRAM)
MY (1) MY140638A (OSRAM)
NL (1) NL300847I2 (OSRAM)
NO (3) NO335195B1 (OSRAM)
NZ (1) NZ533936A (OSRAM)
OA (1) OA12761A (OSRAM)
PE (1) PE20030969A1 (OSRAM)
PL (1) PL220725B1 (OSRAM)
PT (2) PT2279737E (OSRAM)
RS (1) RS52137B (OSRAM)
SI (2) SI1480644T1 (OSRAM)
TN (1) TNSN04137A1 (OSRAM)
TW (1) TWI293071B (OSRAM)
UA (1) UA80271C2 (OSRAM)
UY (1) UY27626A1 (OSRAM)
WO (1) WO2003063864A2 (OSRAM)
ZA (1) ZA200405607B (OSRAM)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
AU2006322564B2 (en) * 2005-12-07 2010-09-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
AU2007309195A1 (en) * 2006-10-23 2008-05-02 Irm Llc Cathepsin proteases inhibitors
WO2008150470A1 (en) * 2007-05-31 2008-12-11 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
PL2666774T3 (pl) * 2008-01-18 2015-06-30 Merck Sharp & Dohme Inhibitory beta-laktamazy
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2346820B1 (en) * 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
EP2657234B1 (en) * 2010-12-22 2017-01-11 Meiji Seika Pharma Co., Ltd. Optically-active diazabicyclooctane derivative and method for manufacturing same
MY165730A (en) 2011-06-17 2018-04-20 Pfizer Anti Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
JP6114275B2 (ja) * 2011-09-13 2017-04-12 ウォックハート リミテッド 窒素含有化合物及びその使用
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CA2868553A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
CN107501264A (zh) 2013-09-24 2017-12-22 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CN111153903A (zh) 2013-10-08 2020-05-15 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
US20170065566A1 (en) * 2014-02-20 2017-03-09 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
EA201691988A1 (ru) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MY196240A (en) * 2014-11-17 2023-03-24 Entasis Therapeutics Ltd Combination Therapy for Treatment Of Resistant Bacterial Infections
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
KR102555657B1 (ko) 2014-12-05 2023-07-18 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 결정 및 안정된 동결 건조 제제의 제조법
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2983674A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
AU2016322283A1 (en) * 2015-09-16 2017-11-09 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
EP3356357A4 (en) 2015-10-02 2019-02-20 LegoChem Biosciences, Inc. COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
EP3156400B1 (en) 2016-05-27 2019-05-15 Valoralia I Más D, SL Dihydrooxadiazine compounds for treating infections and cancer
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
KR102667828B1 (ko) 2016-09-16 2024-05-20 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
EP3577117A1 (en) 2017-02-06 2019-12-11 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11046694B2 (en) 2017-05-08 2021-06-29 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
JP7429988B2 (ja) 2018-08-09 2024-02-09 アンタビオ エスアーエス セリンベータ－ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
EP4146650B1 (en) * 2020-09-01 2026-01-21 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2022233181A1 (en) 2021-05-07 2022-11-10 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
WO1997025309A1 (en) * 1996-01-03 1997-07-17 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
WO1998005659A1 (en) * 1996-08-02 1998-02-12 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
WO1999021855A1 (en) * 1997-10-29 1999-05-06 Smithkline Beecham P.L.C. Pleuromutilin derivatives as antimicrobials
WO2002010172A1 (fr) * 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
DK1227103T3 (da) 1993-09-29 2006-11-27 Univ Maryland Nukleosider og nukleotider med forstörrede ringe
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
CA2327695A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
EP1091944A1 (en) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
KR20010081115A (ko) 1998-12-18 2001-08-27 둘락 노먼 씨. 파르네실 단백질 트랜스퍼라제 억제제
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
JP2004522781A (ja) 2001-02-22 2004-07-29 スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン 腫瘍処置のためのプロドラッグとしてのインドリンおよびテトラヒドロ−キノリン
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
WO1997025309A1 (en) * 1996-01-03 1997-07-17 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
WO1998005659A1 (en) * 1996-08-02 1998-02-12 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
WO1999021855A1 (en) * 1997-10-29 1999-05-06 Smithkline Beecham P.L.C. Pleuromutilin derivatives as antimicrobials
WO2002010172A1 (fr) * 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Also Published As

Publication number Publication date
FR16C1019I2 (fr) 2017-12-29
PL220725B1 (pl) 2015-12-31
AR038234A1 (es) 2005-01-05
YU65804A (sh) 2006-08-17
JO2646B1 (en) 2012-06-17
CY1111061T1 (el) 2015-06-11
OA12761A (fr) 2006-07-04
FR2835186B1 (fr) 2006-10-20
HUS1600055I1 (hu) 2017-01-30
AR100790A2 (es) 2016-11-02
HK1105864A1 (zh) 2008-02-29
EP1480644A2 (fr) 2004-12-01
TNSN04137A1 (fr) 2007-03-12
RS52137B (sr) 2012-08-31
CY2016042I1 (el) 2017-03-15
CR7387A (es) 2010-10-25
HK1077205A1 (zh) 2006-02-10
LTPA2016037I1 (lt) 2017-01-10
MA26351A1 (fr) 2004-10-01
DE60334527D1 (de) 2010-11-25
CO5601014A2 (es) 2006-01-31
PL371601A1 (pl) 2005-06-27
KR20040081473A (ko) 2004-09-21
BR0307267A (pt) 2004-12-07
ES2356813T3 (es) 2011-04-13
CY2016042I2 (el) 2017-03-15
US7612087B2 (en) 2009-11-03
US20100048528A1 (en) 2010-02-25
EP1480644B1 (fr) 2010-10-13
WO2003063864A3 (fr) 2004-03-11
US20110245254A1 (en) 2011-10-06
PT1480644E (pt) 2011-01-17
CA2474043A1 (fr) 2003-08-07
NO2016024I2 (no) 2016-12-15
EP2279737B1 (fr) 2012-10-31
IL163167A (en) 2010-04-15
BRPI0307267B1 (pt) 2016-02-10
CA2474043C (fr) 2011-08-02
ZA200405607B (en) 2005-09-28
DK2279737T3 (da) 2013-02-11
CN1994301A (zh) 2007-07-11
PT2279737E (pt) 2013-02-01
KR100979079B1 (ko) 2010-08-31
AU2003214335B2 (en) 2007-04-05
JP2005523897A (ja) 2005-08-11
HRP20040686A2 (en) 2004-12-31
TWI293071B (en) 2008-02-01
CR20120356A (es) 2012-10-05
UA80271C2 (uk) 2007-09-10
CN100563653C (zh) 2009-12-02
SI1480644T1 (sl) 2011-03-31
ATE484281T1 (de) 2010-10-15
DK1480644T3 (da) 2011-01-24
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
CY1114417T1 (el) 2016-08-31
EA200400981A1 (ru) 2005-02-24
ES2401855T3 (es) 2013-04-25
WO2003063864A2 (fr) 2003-08-07
EA007220B1 (ru) 2006-08-25
CN1655781A (zh) 2005-08-17
FR2835186A1 (fr) 2003-08-01
LTC1480644I2 (lt) 2018-09-10
JP4472346B2 (ja) 2010-06-02
MXPA04006621A (es) 2004-10-04
NO20043587L (no) 2004-08-27
CN101406471A (zh) 2009-04-15
BE2016C069I2 (OSRAM) 2022-05-17
NO335195B1 (no) 2014-10-20
BRPI0307267B8 (pt) 2021-05-25
CN100482225C (zh) 2009-04-29
CL2011000009A1 (es) 2011-03-25
UY27626A1 (es) 2003-08-29
US20090215747A1 (en) 2009-08-27
FR16C1019I1 (fr) 2017-02-03
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
SI2279737T1 (sl) 2013-07-31
EP2279737A1 (fr) 2011-02-02
NO2016024I1 (no) 2016-12-15
MY140638A (en) 2010-01-15
US20050020572A1 (en) 2005-01-27
NL300847I2 (OSRAM) 2017-01-03
ECSP045193A (es) 2004-08-27

Similar Documents

Publication Publication Date Title
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
PA8591701A1 (es) Derivados de pirrolopirimidina
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
DK1678166T3 (da) Proteinkinaseinhibitorer
TW200728307A (en) Novel spirochromanone derivatives
SE0400284D0 (sv) Novel compounds
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
WO2007017728A3 (en) Novel heterocyclic compounds
DK1858861T3 (da) HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
BR122015020406B8 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas
WO2006123229A3 (en) Novel heterocyclic derivatives
TN2011000592A1 (en) Substituted aminopropionic derivatives as neprilysin inhibitors
TN2011000593A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
UA107092C2 (uk) Заміщені похідні карбамоїлметиламінооцтової кислоти як інгібітори nep

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: NOVEXEL, FR

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: ASTRA ZENECA HOLDING FRANCE, FR

PNAN Change of the applicant name, address/residence

Owner name: ASTRA ZENECA HOLDING FRANCE, FR

PPPP Transfer of rights

Owner name: PFIZER IRELAND PHARMACEUTICALS, OPERATIONS SUPPORT

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181224

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200114

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210121

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211228

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230127